Wedbush Has Pessimistic Outlook of argenx FY2026 Earnings

argenx SE (NASDAQ:ARGX) – Wedbush reduced their FY2026 earnings per share estimates for argenx in a note issued to investors on Wednesday, November 20th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $21.65 for the year, down from their prior estimate of $22.14. The consensus estimate for argenx’s current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx’s FY2027 earnings at $34.77 EPS.

Several other brokerages have also recently weighed in on ARGX. Oppenheimer reissued an “outperform” rating and set a $675.00 price target (up previously from $646.00) on shares of argenx in a research report on Thursday. Raymond James reissued a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Citigroup increased their price objective on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Finally, Deutsche Bank Aktiengesellschaft cut argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $630.42.

argenx Stock Performance

Shares of argenx stock opened at $605.92 on Friday. argenx has a 52-week low of $327.73 and a 52-week high of $611.22. The company’s 50 day moving average price is $557.73 and its 200-day moving average price is $488.21. The stock has a market capitalization of $36.23 billion, a price-to-earnings ratio of -688.55 and a beta of 0.61.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same period last year, the company earned ($1.25) EPS.

Hedge Funds Weigh In On argenx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. O Shaughnessy Asset Management LLC increased its holdings in shares of argenx by 32.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 1,460 shares of the company’s stock valued at $575,000 after acquiring an additional 361 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in argenx by 79.3% in the first quarter. Advisors Asset Management Inc. now owns 588 shares of the company’s stock worth $232,000 after buying an additional 260 shares during the last quarter. Toronto Dominion Bank raised its holdings in argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock worth $119,000 after buying an additional 43 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after buying an additional 3,900 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of argenx by 49.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock valued at $2,167,235,000 after buying an additional 1,830,651 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.